Despite decades of research and hundreds of clinical trials, Alzheimer’s disease remains a neurdogenerative condition without a cure. This is due in no small part to the dearth of information on the network of interactions between amyloid beta, tau protein, and the many interacting cells in the brain. We have been applying quantitative phosphoproteomics methods to gain insight into the signaling pathways controlling degeneration in neurons as well as glial cells’ responses in mouse and human models of this disease. We hope to elucidate new drug targets and shed light on the biology of this disease at a systems level.
